Oruka Therapeutics
ORKA
23 hedge funds and large institutions have $5.75M invested in Oruka Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
15% more capital invested
Capital invested by funds: $5.02M → $5.75M (+$730K)
0.18% more ownership
Funds ownership: 1.46% → 1.64% (+0.18%)
12% less funds holding
Funds holding: 26 → 23 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.29M |
| 2 |
Renaissance Technologies
New York
|
+$9.85K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$1.03K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$542 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$424K |
| 2 |
BlackRock
New York
|
-$67.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$48.6K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$45.8K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$34.5K |
ORKA Hedge Fund Activity: Q2 2023 in Review
23 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2023, worth a combined $5.75M — up 15% from $5.02M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORKA and 3 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Western Standard LLC, opening a new position worth an estimated $1.29M. The largest seller was Newtyn Management, cutting an estimated $424K.
- 23 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2023, down from 26 in Q1 2023.
- Funds reported $5.75M of Oruka Therapeutics stock for Q2 2023, up 15% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q2 2023 and 6 closed out, a net change of -3 holders.
- The largest Oruka Therapeutics buyer in Q2 2023 was Western Standard LLC, an estimated $1.29M added.
- The largest Oruka Therapeutics seller in Q2 2023 was Newtyn Management, an estimated $424K sold.
Based on aggregated 13F filings for Q2 2023.